size-exclusion HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
| Property | Value | Notes |
|---|---|---|
| Purity specification (research grade) | Greater than 95 percent by HPLC | Area percent at 220 nm; method dependent |
| Identity confirmation | Mass spectrometry | Observed mass compared with theoretical |
| Residual water | Reported by Karl Fischer titration | Affects peptide content calculation |
| Common synonyms | GLP-1 analog; GLP-1 receptor agonist peptide | Naming varies across catalogs |
| Container material | Low-binding polypropylene | Reduces adsorption at low concentration |
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
==== Other procedures ==== The Delorme procedure (mucosal proctectomy) uses a perineal approach. Delorme's procedure has similar results to STARR for IRP. The procedure may improve symptoms of chronic constipation, but may be less successful for symptoms of fecal incontinence. Suture rectopexy may be suitable for both males and females, but it may have a better outcome in males, possibly due to undetected sphincter defects in females. Posterior rectopexy is used for external rectal prolapse. Posterior rectopexy involves dissection of the posterior (back) and lateral surfaces of the rectum, which may damage the autonomic nerves from the pelvic plexus to the rectum. Therefore, posterior rectopexy may improve symptoms of fecal incontinence, but may worsen constipation. Posterior rectopexy for IRP is controversial.
=== RNase MRP === Protein subunits of RNase P are shared with RNase MRP, an evolutionarily related catalytic ribonucleoprotein involved in processing of ribosomal RNA in the nucleolus and DNA replication in the mitochondrion.
=== X-ray spectrometer === The most practical application of 244Cm—though rather limited in total volume—is as an α-particle source in alpha particle X-ray spectrometers (APXS). These instruments were installed on the Sojourner, Mars, Mars 96, Mars Exploration Rovers and Philae comet lander, as well as the Mars Science Laboratory to analyze the composition and structure of the rocks on the surface of planet Mars. APXS was also used in the Surveyor 5–7 moon probes but with a 242Cm source. An elaborate APXS setup has a sensor head containing six curium sources with a total decay rate of several tens of millicuries (roughly one gigabecquerel). The sources are collimated on a sample, and the energy spectra of the alpha particles and protons scattered from the sample are analyzed (proton analysis is done only in some spectrometers). These spectra contain quantitative information on all major elements in the sample except for hydrogen, helium and lithium.
Sources: en.wikipedia.org
They have improved a process from Monsanto by using ultrafiltration to concentrate the incoming lignosulfonates, which reduces the amount of NaOH used and waste produced. The basic chemistry is unchanged: alkaline oxidation using a metal catalyst such a copper salt. According to Scientific American, vanillin produced this way contains aromatic impurities that add strength and creaminess to its flavor. This is probably due to acetovanillone being present.
2 of 7; p=0.05); (2) greater increases in pulmonary artery end diastolic pressure in those without collaterals (p=0.05); and (3) great cardiac vein flow that was significantly greater in those with collaterals than in those without them. Spasm resulted in mild angina associated with slight elevation of pulmonary artery end diastolic pressure and ST depression when collaterals were present rather than elevation and lower cardiac lactate production, suggesting strongly that collaterals do salvage myocardium when ischemia is produced by spasm. Whether angina causes collateral development is still debatable, but at least one investigator, Fujita, believes that angina is either symptomatic of, or somehow promotes the development of, collateral circulation, and, in any case, sometimes precedes, and often prevents, infarction by relieving the critically occluded vessel before thrombosis can occur. Examining 37 patients who underwent intercoronary thrombolysis within six hours of MI, Fujita found that 2 of 19 patients without preinfarct angina had collaterals and 9 of 18 patients with angina had them. No other variables pertaining to collateral development distinguished the groups. Fujita therefore suggests that the absence of symptomatic angina may not always portend favorable developments, and infarct prevention must surely be targeted to those with coronary disease who are without symptoms, as they may be without the protective effects of collateral development provoked by the presence of angina.
=== Reaction === Limulus clotting enzyme uses 2H2O to cleave the Arg18-Gly19 and Arg46-Thr47 linkages in coagulogen, forming coagulin + two peptide products. This process activates coagulin, allowing it to gel and form clots around bacterial invaders. The reaction is hydrolytic and catalyzed by the His-Asp-Ser triad in the active site. The hydroxyl group in serine acts as a nucleophile, attacking the carbonyl carbon in the peptide bond. Histidine’s nitrogen atom accepts the hydrogen from serine’s hydroxyl group to make serine a stronger nucleophile. Aspartic acid forms hydrogen bonds with histidine to make this nitrogen atom more electronegative and therefore more likely to accept the hydrogen. The nucleophilic attack results in the peptide bond breaking, allowing one peptide fragment to be released. A water molecule is then deprotonated by the histidine. The resulting hydroxyl acts as a nucleophile to break the bond between the serine and the carbonyl, releasing the rest of the protein. The process is then repeated at the other peptide bond.
Sources: en.wikipedia.org
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.
Each cycle exposes the peptide to ice-liquid interfaces where unfolding and aggregation can occur. Aggregates may not redissolve and can alter measured activity. Aliquoting before the first freeze reduces the number of cycles any single portion experiences.
It usually reports purity by HPLC, identity by mass spectrometry, peptide content, appearance, and residual moisture or counterion content. The analytical method behind each value should be stated. Acceptance criteria are set by the supplier or the buyer's specification.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.